



Press Release

Valbiotis expands its Valbiotis^{PLUS®} range with the new Menopause & Perimenopause solution

11 products now marketed through pharmacy and e-commerce channels

La Rochelle, February 2, 2026 (5:40 pm CEST) – **Valbiotis** (FR0013254851 - ALVAL, PEA / PME eligible), a French laboratory specializing in the development and distribution of scientifically tested dietary supplements designed to support health at every stage of life, **announces the launch of Valbiotis^{PLUS®} Menopause & Perimenopause** on Tuesday, February 3. This innovation addresses a major health challenge: tailored support for women's health, particularly during the key stages of perimenopause and menopause.

This new launch, to be rolled out in both pharmacies and on the Company's e-commerce site, further strengthens the Valbiotis^{PLUS®} range, which addresses key peripheral factors of cardio-metabolic balance and already includes seven other supplements: Marine Collagen Beauty, Marine Collagen Joints, Sleep, Serenity, Multivitamins, Omega-3 and Magnesium.

These solutions are available in pharmacies and online alongside the three products in the Valbiotis^{PRO®} range (Cholesterol, Metabolic Health, Cardiocirculation), based on proprietary clinical studies.

The Company will therefore see a full "range effect" on pharmacy shelves, with a total of eleven Valbiotis products now listed, compared with only five in the third quarter of 2025. This range effect will contribute to the strong sales growth expected by the Company this year (see our [press release of January 27, 2025](#)).

A comprehensive approach through the new health program, "Menopause and Slowed Metabolism", backed by a high-impact marketing and communications campaign

Valbiotis^{PLUS®} Menopause & Perimenopause is a hormone- and phytoestrogen-free nutritional solution based on a selection of seven active ingredients, supported by a robust body of scientific literature.

Menopause is a major health issue, affecting 14 million women in France. Pharmacy sales of dietary supplements addressing premenopause- and menopause-related conditions totaled €21.4 million in 2024, up more than 9% year-over-year and more than 18% compared with two years earlier¹.

To mark this launch, Valbiotis has developed **"Menopause and Slowed Metabolism", a new dedicated health program** designed to provide a synergistic and comprehensive approach to a major health issue: cardiometabolic imbalances linked to declining estrogen levels during menopause. The program

¹ Source: "The menopause market" study published by Les Echos Études in partnership with GERS Data (September 2024)

combines two complementary solutions, Valbiotis^{PLUS®} Menopause & Perimenopause and Valbiotis^{PRO®} Metabolic Health, a clinically tested formula to help limit excess abdominal fat and support the maintenance of normal blood glucose levels.

Over the coming weeks, a substantial communications and marketing campaign will be rolled out to promote this health program, targeting both B2B (pharmacy) and B2C (online) audiences. This initiative will be deployed to enhance visibility across multiple touchpoints: in pharmacies (point-of-sale advertising and activations), online (targeted content), among prescribers (dedicated webinars), as well as in the media (press conferences, advertising plan) and on social networks.

Shareholder Benefit

20% discount on Valbiotis^{PRO®} and Valbiotis^{PLUS®} products, granted by customer service (service-client@valbiotis.com) upon presentation of proof of ownership of at least 85 shares

Terms and Conditions: [Click here](#)

About Valbiotis

Valbiotis is a French laboratory specializing in the creation and distribution of dietary supplements scientifically tested to maintain health at every stage of life. Through an innovative approach combining scientific excellence, plant expertise and a wealth of natural ingredients, Valbiotis offers a new generation of dietary supplements to support cardio-metabolic balance and well-being, and address everyday health issues such as sleep, fatigue, mood management, immunity and vitality. Created at the beginning of 2014 in La Rochelle, France, Valbiotis has forged numerous partnerships with leading academic centers.

Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information on Valbiotis[®], please visit: www.valbiotis.com

Contacts

Corporate Communication / **Valbiotis**

Caroline Lamberti

+ 33 6 77 82 56 88

caroline.lamberti@valbiotis.com

Financial communication / **Seitosei.Actifin**

Marianne Py

+33 6 85 52 76 93

marianne.py@seitosei-actifin.com

Press Relations / **LJ Com by JIN**

Valentine Martin

+33 6 32 29 43 82

v.martin@ljcom.net



Name: Valbiotis

ISIN Code: FR0013254851

Ticker Symbol: ALVAL

EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the Valbiotis Universal Registration Document, filed with the French Financial Markets Regulator (AMF) on April 26, 2023, under number D.23-0347, as well as in its Amendment filed with the AMF on December 11, 2023, under number D.23-0347.A01. These documents are available on the Company's website (www.valbiotis.com).
This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis' shares or financial securities in any country.